Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 and Pertuzumab in HER2-Positive Breast Cancer
NCT07528898Phase 2Not yet recruiting
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- May 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab rezetecan in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Planned start May 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07528898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528898.